This review discusses the rationale for the combination and provides a 4-year efficacy update of data from the CheckMate 067 trial of nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone in advanced melanoma. It includes long-term survival, time without subsequent therapy, patients free of subsequent therapy, and efficacy outcomes for those who discontinued.
Commentary and recommendations from Dr Megan Lyle, a medical oncologist at the Liz Plummer Cancer Centre (Cairns Hospital). She previously completed a clinical research fellowship at Melanoma Institute Australia in Sydney.
Please login below to download this issue (PDF)